Ocumension Acquires Implant Therapy for Retina Diseases in $119 Million Deal

Shanghai Ocumension Therapeutics acquired Greater China rights to Alimera’s implant therapy for diabetic macular edema and other retina diseases in a $119 million agreement. Alimera is an Atlanta area company. Ocumension will develop Iluvien® 0.19mg fluocinolone acetonide intravitreal implant for use in Greater China. It made a $10 million equity investment in Alimera, paid $10 million upfront and will be responsible for up to $89 million in sales-based milestones. Ocumension will will also issue four-year warrants for 1 million of its shares to Alimera. More details.... Stock Symbol: (HK: 1477) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.